Is UNII-N3RQ532IUT Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use UNII-N3RQ532IUT? Is UNII-N3RQ532IUT safe for nursing mother and child? Does UNII-N3RQ532IUT extracts into breast milk? Does UNII-N3RQ532IUT has any long term or short term side effects on infants? Can UNII-N3RQ532IUT influence milk supply or can UNII-N3RQ532IUT decrease milk supply in lactating mothers?

• DrLact safety Score for UNII-N3RQ532IUT is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of UNII-N3RQ532IUT may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that UNII-N3RQ532IUT may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using UNII-N3RQ532IUT .
• It is recommended to evaluate the advantage of not breastfeeding while using UNII-N3RQ532IUT Vs not using UNII-N3RQ532IUT And continue breastfeeding.
• While using UNII-N3RQ532IUT Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

A published case of infant hypothyroidism. Others have reported lab controlled cases with harmless effect in breastfed babies.

Breastmilk and infant serum levels of UNII-N3RQ532IUT and its active metabolite are somewhat unpredictable, but can be high during breastfeeding. The infant receives an estimated dose of UNII-N3RQ532IUT plus desethylUNII-N3RQ532IUT ranging from 3.5 to 45% of the mother's weight-adjusted UNII-N3RQ532IUT dose, with a median dose of about 11%.[1][2][3][4] Infant serum levels of the drug plus metabolite range from 14 to 74% of simultaneous maternal levels, with the higher values reflecting transplacental passage of the drug.[2][3][4] In addition to possible cardiac effects, these compounds contain a large amount of iodine which may be released during metabolism. Thyroid dysfunction was reported in one breastfed infant. Even if the drug were discontinued at birth, the mother would continue to excrete UNII-N3RQ532IUT and its metabolite (and possibly large amounts of iodine) into breastmilk for days to weeks. Some investigators believe that breastfeeding can be undertaken during maternal UNII-N3RQ532IUT use with periodic monitoring of infant cardiac and thyroid function status,[5][6] especially if only a single dose of UNII-N3RQ532IUT is given.[7] Infant serum levels of UNII-N3RQ532IUT and desethylUNII-N3RQ532IUT may be useful for ruling out cardiac effects of the drug. If hypothyroidism develops, therapy should be promptly initiated.

Several infants who breastfed without apparent harm during maternal UNII-N3RQ532IUT therapy have been reported.[2][3][4][10] One mother took UNII-N3RQ532IUT during the last 5 weeks of pregnancy and until one week after delivery. She was also taking metoprolol throughout pregnancy and at the time of delivery. Possible signs of hypothyroidism occurred transiently in her breastfed infant at 9 and 24 days of age. This was possibly caused by UNII-N3RQ532IUT or iodine from UNII-N3RQ532IUT in breastmilk, although residual UNII-N3RQ532IUT from transplacental passage is also a possible contributing factor; no abnormalities in cornea or the lungs were found.[4]

Relevant published information was not found as of the revision date. However, if UNII-N3RQ532IUT causes hypothyroidism in the mother, her milk supply could be diminished.